• Pol II Degradation Triggers Cell Death Beyond Transcription

  2026-04-27

  This article examines how degradation of RNA Polymerase II (Pol II) can activate cell death independently of transcriptional shutdown, as demonstrated in the referenced preprint. The findings reframe our understanding of DNA damage response and offer new directions for mechanistic cancer biology research.

• Capsaicin Beyond TRPV1: Epigenetic Modulation and Oncology I

  2026-04-27

  Explore how Capsaicin acts not only as a TRPV1 ion channel activator but as a potent KDM1A/LSD1 inhibitor, revealing new avenues in epigenetic cancer modulation. This article delivers a uniquely deep, evidence-driven analysis of Capsaicin’s dual mechanisms and translational value.

• ML133 HCl: Precision Potassium Channel Inhibition in Vascula

  2026-04-26

  ML133 HCl stands out as a highly selective potassium channel inhibitor, enabling targeted investigation of Kir2.1 function in cardiovascular and pulmonary artery smooth muscle cell research. Its robust specificity and reproducibility accelerate workflows and sharpen mechanistic insights into vascular remodeling and disease modeling.

• ATM Inhibition Promotes Macropinocytosis and Metabolic Adapt

  2026-04-25

  The referenced study uncovers how ATM kinase inhibition drives metabolic adaptation in cancer cells by inducing macropinocytosis. This mechanistic link reveals a metabolic vulnerability with implications for targeting nutrient acquisition pathways in ATM-deficient tumors.

• Spider Toxin v-Agatoxin-IVA Reveals Calcium Channel Diversit

  2026-04-24

  Sidach and Mintz's landmark study redefines the pharmacological selectivity of the spider toxin v-Agatoxin-IVA, demonstrating that its low-affinity blockade extends beyond classic P-type calcium channels to include N-type and Q-type currents in mammalian neurons. This nuanced pharmacological profiling has direct implications for both the classification of neuronal calcium channels and the design of selective neurophysiological experiments.

• Rucaparib (AG-014699): Precision PARP1 Inhibition in DNA Dam

  2026-04-24

  Rucaparib (AG-014699) empowers DNA damage response studies through unmatched PARP1 inhibition and radiosensitization, especially in PTEN-deficient cancer models. This guide details advanced workflows, optimization strategies, and practical troubleshooting to extract maximum value from APExBIO's high-performance reagent.

• Rosiglitazone (Brl-49653): Optimizing PPARγ Activation in Ad

  2026-04-23

  Rosiglitazone (Brl-49653) empowers metabolic researchers with precise, reproducible PPARγ activation, enabling advanced adipogenesis and insulin sensitivity studies. This guide translates recent breakthroughs—including functional rescue in rare PPARG variants—into actionable workflows and troubleshooting strategies.

• Optimizing Protein Extraction with Protease Inhibitor Cockta

  2026-04-23

  Ensure uncompromised protein integrity and phosphorylation status with the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO). This EDTA-free formulation from APExBIO delivers reliable inhibition of serine, cysteine, and acid proteases—essential for advanced signaling, enzyme, and post-translational modification studies.

• Surfactant-Derived LNPs Enable Efficient mRNA Delivery to Ma

  2026-04-22

  This study establishes a dual-component lipid nanoparticle (LNP) system, leveraging surfactant-derived ionizable lipids, for safe and effective mRNA delivery into macrophages. The findings advance strategies for genetic engineering of hard-to-transfect immune cells, with implications for both therapeutic development and transfection assay optimization.

• ARCA EGFP mRNA: Optimizing Fluorescence-Based Transfection C

  2026-04-22

  ARCA EGFP mRNA sets a new benchmark for fluorescence-based transfection assays in mammalian cells, enabling direct, quantitative assessment of gene delivery efficiency. Discover streamlined workflows, troubleshooting strategies, and comparative insights rooted in recent advances in nanoparticle-mediated nucleic acid delivery.

• Fluorescein TSA Fluorescence System Kit for Sensitive Signal

  2026-04-21

  The Fluorescein TSA Fluorescence System Kit leverages tyramide signal amplification for ultrasensitive detection of low-abundance biomolecules in IHC, ICC, and ISH workflows. This article breaks down experimental best practices, advanced use cases, and practical troubleshooting, contextualized by recent angiogenesis research and APExBIO’s workflow innovations.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-04-21

  Schwartz's dissertation advances in vitro evaluation of anti-cancer drugs by distinguishing proliferative arrest from cell death through dual-metric quantification, revealing nuanced drug effects and timing. This approach provides researchers with improved strategies for interpreting drug responses and optimizing assay design.

• HATU: High-Efficiency Peptide Synthesis with Workflow Insigh

  2026-04-20

  HATU empowers peptide synthesis chemistry with rapid, high-yield amide bond formation, reducing bottlenecks in complex inhibitor development. This article distills robust experimental workflows, troubleshooting tactics, and lessons from recent nanomolar inhibitor research, guiding users to maximize HATU’s efficiency in advanced biochemical settings.

• Ciprofloxacin Sensitizes Tumor Cells to Ferroptosis via Mito

  2026-04-20

  This study uncovers a novel mechanism by which ciprofloxacin (CFX) enhances RSL3-induced ferroptosis in cancer cells through mitochondrial zinc accumulation mediated by the STING1–CAV2 pathway. The findings reveal the context-dependent, dual role of CFX in ferroptosis regulation and suggest actionable strategies for targeting tumor cell viability.

• Fluorouracil in Solid Tumor Research: Protocols and Pitfalls

  2026-04-19

  Fluorouracil (Adrucil) from APExBIO empowers rigorous, reproducible solid tumor research by targeting DNA synthesis and overcoming common resistance mechanisms. This article delivers stepwise protocols, troubleshooting insights, and evidence-based guidance for colon, breast, and ovarian cancer models.

15709 records 1/1048 page Next 12345 下5页 Last page